Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $250 to $310.
Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $250 to $310.